Liver-directed therapies for fibrolamellar carcinoma: A single-center experience.

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.052985

Sam Son, Akshaar Brahmbhatt, Ken Zhao, Brett Marinelli, James Harding, William Jarnagin, Ghassan K Abou-Alfa, Hooman Yarmohammadi

{"title":"Liver-directed therapies for fibrolamellar carcinoma: A single-center experience.","authors":"Sam Son, Akshaar Brahmbhatt, Ken Zhao, Brett Marinelli, James Harding, William Jarnagin, Ghassan K Abou-Alfa, Hooman Yarmohammadi","doi":"10.32604/or.2024.052985","DOIUrl":null,"url":null,"abstract":"Background: This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma (FLC) treated with liver-directed therapies (LDT).Methods: In this single-center retrospective study, all patients diagnosed with FLC who underwent LDT were identified. Between July 2012 and July 2023, six patients were identified. One patient was excluded due to bleeding. Demographic and clinical parameters were recorded. Complications within 30 days of the LDT were evaluated. Radiological treatment responses at 1, 6, and 12 months were assessed per mRECIST.Results: A total of five patients, which included three females and two males, were reviewed. Three patients were treated with transarterial hepatic embolization (TAE; n = 3), transarterial radioembolization (TARE; n = 1), and combined TAE + radiofrequency ablation (n = 1). The objective response rate at one month was 80% [CR = 2 (40%), PR = 2 (40%), and SD = 1 (20%)]. At 12 months (n = 4), two patients demonstrated CR (50%) and two demonstrated PR (50%). Overall survival from LDT at five years was 50%. There was no 30-day mortality among this group of patients or any adverse event attributable to the LDT.Conclusion: TAE, TARE, and ablation are safe and effective therapeutic options for FLC. Based on this study and previously published case reports, ablation and TARE yielded the most favorable results.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 12","pages":"1831-1836"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.052985","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma (FLC) treated with liver-directed therapies (LDT).

Methods: In this single-center retrospective study, all patients diagnosed with FLC who underwent LDT were identified. Between July 2012 and July 2023, six patients were identified. One patient was excluded due to bleeding. Demographic and clinical parameters were recorded. Complications within 30 days of the LDT were evaluated. Radiological treatment responses at 1, 6, and 12 months were assessed per mRECIST.

Results: A total of five patients, which included three females and two males, were reviewed. Three patients were treated with transarterial hepatic embolization (TAE; n = 3), transarterial radioembolization (TARE; n = 1), and combined TAE + radiofrequency ablation (n = 1). The objective response rate at one month was 80% [CR = 2 (40%), PR = 2 (40%), and SD = 1 (20%)]. At 12 months (n = 4), two patients demonstrated CR (50%) and two demonstrated PR (50%). Overall survival from LDT at five years was 50%. There was no 30-day mortality among this group of patients or any adverse event attributable to the LDT.

Conclusion: TAE, TARE, and ablation are safe and effective therapeutic options for FLC. Based on this study and previously published case reports, ablation and TARE yielded the most favorable results.

查看原文本刊更多论文

纤维母细胞癌的肝脏导向疗法：单中心经验。

背景：本文旨在介绍单个机构对纤维母细胞瘤（FLC）患者进行肝脏导向疗法（LDT）治疗的结果：在这项单中心回顾性研究中，确定了所有确诊为FLC并接受LDT治疗的患者。2012年7月至2023年7月期间，共确定了6名患者。其中一名患者因出血而被排除。记录了人口统计学和临床参数。评估了 LDT 术后 30 天内的并发症。根据 mRECIST 评估了 1、6 和 12 个月的放射治疗反应：共审查了五名患者，其中包括三名女性和两名男性。三名患者接受了经动脉肝栓塞（TAE；n = 3）、经动脉放射栓塞（TARE；n = 1）和TAE + 射频消融联合治疗（n = 1）。一个月的客观反应率为 80% [CR = 2 (40%)、PR = 2 (40%)、SD = 1 (20%)]。12 个月时（n = 4），两名患者表现为 CR（50%），两名表现为 PR（50%）。LDT五年总生存率为50%。这组患者中没有 30 天死亡病例，也没有发生任何可归因于 LDT 的不良事件：结论：TAE、TARE 和消融术是 FLC 安全有效的治疗方案。结论：TAE、TARE 和消融术是治疗 FLC 的安全有效的治疗方案。根据本研究和之前发表的病例报告，消融术和 TARE 取得了最理想的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.